



Universiteit  
Leiden  
The Netherlands

## Insulin-like growth factor-1 and Duchenne muscular dystrophy

Yavaş, A.

### Citation

Yavaş, A. (2025, March 26). *Insulin-like growth factor-1 and Duchenne muscular dystrophy*. Retrieved from <https://hdl.handle.net/1887/4209128>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4209128>

**Note:** To cite this publication please use the final published version (if applicable).

## List of Publications

Yavas A, Weij R, van Putten M, Kourkouta E, Beekman C, Puoliväli J, Bragge T, Ahtoniemi T, Knijnenburg J, Hoogenboom ME, Ariyurek Y, Aartsma-Rus A, van Deutekom J, Datson N. Detailed genetic and functional analysis of the hDMDdel52/*mdx* mouse model. PLoS One. 2020 Dec 23;15(12):e0244215. doi: 10.1371/journal.pone.0244215.

Yavas A, van Putten M, Aartsma-Rus A. Antisense Oligonucleotide-Mediated Downregulation of IGFBPs Enhances IGF-1 Signaling. Journal of Neuromuscular Diseases. 2024;11(2):299-314. doi:10.3233/JND-230118

Yavas A, van Putten M, Ariyurek Y, Aartsma-Rus A. Antisense oligonucleotide-mediated redirection of *Igf1* alternative polyadenylation, *submitted*

## List of Abbreviations

|            |                                          |
|------------|------------------------------------------|
| 2OMePS     | 2'-O-methyl phosphorothioate             |
| AAV        | Adeno-associated viruses                 |
| ALS        | Acid-labile subunit                      |
| ANOVA      | Analysis of variance                     |
| AON        | Antisense oligonucleotides               |
| AS         | Alternative splicing                     |
| BAM        | Binary alignment map                     |
| BMD        | Becker muscular dystrophy                |
| DE         | Differentially expressed                 |
| DGE        | Differential gene expression             |
| DMD        | Duchenne muscular dystrophy              |
| DAPC       | Dystrophin-associated protein complex    |
| DSB        | Double-strand break                      |
| DSE        | Downstream elements                      |
| EBD        | Evan's blue dye                          |
| ECM        | Extracellular matrix                     |
| EMA        | European Medicines Agency                |
| E-peptides | Extension peptides                       |
| ESE        | Exonic splicing enhancer                 |
| ESS        | Exonic splicing silencer                 |
| FDA        | Food and Drug Administration             |
| FISH       | Fluorescent <i>in situ</i> hybridization |
| GH         | Growth hormone                           |
| GO         | Gene ontology                            |
| gRNA       | guide RNA                                |
| HDAC       | Histone deacetylase                      |
| HDR        | Homology-directed repair                 |
| IGF-1      | Insulin-like growth factor-1             |
| IGF-1R     | IGF-1 receptor                           |
| IGFBPs     | IGF-binding proteins                     |
| IRS-1      | Insulin receptor substrate-1             |
| ISE        | Intronic splicing enhancer               |
| ISS        | Intronic splicing silencer               |
| MD         | Muscular dystrophies                     |
| MGF        | Mechano growth factor                    |
| NHEJ       | Non-homologous end joining               |
| PAS        | Polyadenylation signal                   |
| PMO        | Phosphorodiamidate morpholino            |

|              |                                                |
|--------------|------------------------------------------------|
| rhIGF-1      | Recombinant IGF-1                              |
| SMA          | Spinal muscular atrophy                        |
| SRSF1        | Serine-arginine protein splicing factor-1      |
| TALEN        | Transcription activator-like effector nuclease |
| TGF- $\beta$ | Transforming growth factor-beta                |
| USE          | Upstream elements                              |
| UTR          | Untranslated regions                           |

## Curriculum Vitae

Alper Yavas was born on the 4<sup>th</sup> of September 1989, in İnegöl, Türkiye. He completed his Bachelor's degree in Molecular Biology and Genetics in Istanbul Technical University, and his Master's degree in Middle East Technical University in Ankara. During his graduation studies, he worked on several topics including plant functional genomics and microbial genetics. In 2019, he moved to the Netherlands to embark on his PhD journey in the Department of Human Genetics, at the Leiden University Medical Center (LUMC) in the group of Prof. dr. Annemieke Aartsma-Rus. In his PhD studies, he focused on developing AON-mediated strategies for treating secondary defects in Duchenne muscular dystrophy by modulation of IGF-1 signaling and posttranscriptional events; alternative splicing and polyadenylation. He also worked on genetic and functional characterization of the humanized mouse model (hDMDdel52/*mdx*) that allows testing human-specific AONs in mice. In February 2024, he began working as a postdoctoral researcher in the Pang Lab, at the Department of Cell and Chemical Biology, LUMC. He is currently studying the function of the non-coding human genome using state-of-the-art genome-editing tools.

## Acknowledgements

As I bring this important chapter of my life to a close, I am very happy with the decision I made five years ago to move to the Netherlands with my wife. It has proven to be one of the best choices I have ever made, opening doors to opportunities and experiences that have enriched both my personal and professional life.

Dear Annemieke, it has been a privilege to work under your guidance during my PhD. Thank you for being such a kind, supportive mentor and a truly inspiring scholar.

Dear Maaïke, your support and encouragement over the years have been invaluable with your unique way of thinking that simplifies life's complexities, and I've benefited greatly from it. Thank you for everything!

Dear Erik, thank you for sharing diverse perspectives and smart ideas during our meetings. Your contributions have been insightful.

Sarah, sometimes it feels as if you're still sitting right next to me. Your friendship made this journey much more enjoyable and manageable. Thank you for the endless support, the wonderful times we shared at LUMC and abroad, and for always reminding me about deadlines.

Kayleigh, thank you for being my paranymph and for all the support throughout my PhD journey. Your presence has made this experience more fun and manageable.

To my fellow group members—Davy, Christa, Pietro, Laura, Anne-Fleur, Minou, Remko, Anouk, Marlen, Bianca, Laurie, Willeke, Elsa, Tom, Barry, Ronald, Linda, Elena—thank you for the laughs, the support, and the shared experiences. Davy, special thanks to you for all the *in vitro* and *in vivo* training and for sharing your brewing wisdom.

I would also like to thank the Vico Therapeutics team (formerly Biomarin)—Nicole, Rudie, and Judith—for the fruitful collaborations and insightful scientific discussions.

A heartfelt thanks to Yavuz Abi for all the scientific and personal conversations. I deeply admire your passion for the field and have learned so much from you.

I would like to extend my gratitude to my current lab members at the Pang Lab. I am truly grateful for the collaborative and supportive environment you have created.

To my parents and my sister, this journey has been long and, at times, challenging. Your love and support made it not only bearable but deeply meaningful. Thank you for being my constant source of strength.

Lastly, to my dearest wife, Dilan—your love and belief in me have been my greatest motivation. When I shared my project ideas with you over dinner or during our walks, your confidence in my ability to bring them to life often surpassed my own. Your unwavering presence has been my greatest comfort. I am so grateful to have you by my side. Could you have imagined this?